Table 1 Plasma osteopontin levels in head and neck cancer and cervix cancer patients as measured using two different ELISA systems.
patient group | assay A | assay B | individual factors (assay B/A) | |
|---|---|---|---|---|
osteopontin (ng/ml) | osteopontin (ng/ml) | |||
all samples | mean ± SD | 13.9 ± 21.0 | 786.0 ± 442.5 | 77.1 ± 41.4 |
(n = 88) | median (range) | 9.8 (3.5–189.5) | 667.0 (148.8–2095.0) | 74.6 (2.0–217.9) |
head and neck cancer | mean ± SD | 16.1 ± 31.1 | 794.3 ± 467.2 | 76.3 ± 38.9 |
(n = 34) | median (range) | 10.4 (3.8–189.5) | 650.2 (148.8–1841.0) | 76.5 (5.7–184.5) |
cervix cancer | mean ± SD | 12.4 ± 11.0 | 780.7 ± 430.6 | 77.6 ± 43.3 |
(n = 54) | median (range) | 9.5 (3.5–80.5) | 667.0 (155.5–2095.0) | 70.3 (2.0–217.9) |